Lymphocyte reconstitution after DMF discontinuation in clinical trial and real-world patients with MS
Andrew Chan, John Rose, Enrique Alvarez, Amit Bar-Or, Helmut Butzkueven, Robert J Fox, Ralf Gold, Mark Gudesblatt, Jodi Haartsen, Tim Spelman, Katy Wright, Diana Ferraro, Patrizia Sola, Suzanne Hodgkinson, Tomas Kalincik, Jeannette Lechner-Scott, Christopher McGuigan, Karen Spach, Chongshu Chen, Sami Fam Show all
Neurology Clinical Practice | LIPPINCOTT WILLIAMS & WILKINS | Published : 2020
BackgroundDelayed-release dimethyl fumarate (DMF) has demonstrated robust efficacy in treating patients with relapsing-remitting multiple sclerosis. Decreases in absolute lymphocyte count (ALC) are a well-known pharmacodynamic effect of DMF treatment, but lymphocyte recovery dynamics are not well characterized after discontinuation of DMF.MethodsData sources included the Biogen DMF integrated clinical trial data set, a retrospective US chart abstraction study, and data from MSBase. We assessed rate and time course of lymphocyte reconstitution after DMF discontinuation.ResultsThe majority of patients who developed lymphopenia while treated with DMF and subsequently discontinued treatment expe..View full abstract
This study was sponsored by Biogen (Cambridge, MA). Writing and editorial support for the preparation of this manuscript was provided by Excel Scientific Solutions (Fairfield, CT): funding was provided by Biogen.